A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.
Meet the Innovator of the Year for Men's Health honoree for Atlanta Business Chronicle's Health Care Champion Awards.
Irish Examiner on MSN18h
I was shocked to be diagnosed with triple-negative breast cancer in my 40sCiara Foskin’s diagnosis came out of the blue. She is part of a small cohort of women under 50 who develop triple-negative ...
The HER2 gene makes a protein called HER2 (human epidermal growth factor receptor 2). This protein is found on the surface of all breast cells and that helps them grow. If the HER2 gene ...
Alejandro Rios Hoyo discussed findings on a subset of hormone receptor–positive, HER2-negative breast cancers classified as ...
TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.
Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...
Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
Genetic testing, via germline and somatic testing, is crucial in breast cancer to understand inherited risks and tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback